Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Core Viewpoint - Zealand Pharma has appointed Utpal Singh as Chief Scientific Officer to enhance its peptide therapeutics discovery efforts, aiming to lead in obesity management and related complications [2][8]. Company Overview - Zealand Pharma A/S is a biotechnology company focused on innovative peptide-based medicines, with over 10 drug candidates advancing into clinical development, including two that have reached the market [5][6]. - The company has established development and commercial partnerships with various pharmaceutical companies [5]. Leadership Appointment - Utpal Singh brings nearly 25 years of pharmaceutical experience, previously serving as Senior Vice President of Small Molecule Discovery at Eli Lilly, where he led significant advancements in drug discovery [3][4]. - His role will involve leading discovery research and translational sciences, with a focus on integrating data science and machine learning into the drug discovery process [4][8]. Strategic Goals - The company aims to expand its peptide discovery capabilities to support innovative therapies, particularly targeting obesity and related health issues [4][8]. - Singh's leadership is expected to strengthen the foundation for growth and drive the development of life-changing medicines [4][8].